The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Patterns of Response and Progression to Immunotherapy
Abstract
Patterns of response and progression to immunotherapy may differ from those observed with drugs such as chemotherapy and molecularly targeted agents. Specifically, some patients experience a response after progression that is retrospectively named pseudoprogression. This phenomenon of pseudoprogression, first reported in patients with melanoma who were treated with ipilimumab, has led to the development of immune-specific related response criteria, such as irRC (immune-related response criteria), irRECIST (immune-related RECIST), and iRECIST (immunotherapy RECIST) that allow continued treatment beyond progression. However, the rate of pseudoprogression has never exceeded 10% of patients across tumor types. Conversely, rapid progressions after immunotherapy, called hyperprogressions, were reported by three different teams in 9% to 29% of patients treated with immunotherapy. Because of the absence of control arms in these studies, it remains to be determined whether these rapid progressions reflect a detrimental effect of immunotherapy in these patients. Finally, preliminary data suggest that immunotherapy might also affect response to subsequent standard therapies. In total, given the rarity of pseudoprogressions across tumor types and the recent description of hyperprogressions, classic RECIST remains a reasonable and rational method to assess response to immunotherapy. Continuation of treatment beyond progression should be proposed only in carefully selected patients whose clinical conditions have improved and who have not experienced severe toxicities. Although there is an urgent need to identify predictive biomarkers of efficacy to immunotherapy, there is an equally urgent need to identify predictive factors of progression or possibly hyperprogression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationReporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationNivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (1976) · Journal of Urology · doi:10.1016/s0022-5347(17)58737-6 · Cited by 1,791
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Choi, H., Charnsangavej, C., Faria, S. C., Macapinlac, H. A., Burgess, M. A., Patel, S. R., Chen, L. L., Podoloff, D. A., & Benjamin, R. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3049 · Cited by 1,520
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Champiat, S., Dercle, L., Ammari, S., Massard, C., Hollebecque, A., Postel-Vinay, S., Chaput, N., Eggermont, A., Marabelle, A., Soria, J.-C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1741 · Cited by 1,190
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,180
Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00175-3 · Cited by 1,121
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944
(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831
Hodi, F. S., Hwu, W.-J., Kefford, R., Weber, J. S., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0391 · Cited by 734
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F., Hersey, P., & Scolyer, R. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2479 · Cited by 652
Self-citationSaâda-Bouzid, E., Defaucheux, C., Karabajakian, A., Coloma, V. P., Servois, V., Paoletti, X., Even, C., Fayette, J., Guigay, J., Loirat, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx178 · Cited by 596
Self-citationThe anticancer immune response: indispensable for therapeutic success?
Zitvogel, L., Apetoh, L., Ghiringhelli, F., André, F., Tesniere, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 573
Frenel, J.-S., Le Tourneau, C., O’Neil, B., Ott, P. A., Piha-Paul, S. A., Gomez-Roca, C., van Brummelen, E. M. J., Rugo, H. S., Thomas, S., Saraf, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5471 · Cited by 531
Self-citationPeng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525
Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0895 · Cited by 522
Improved Endpoints for Cancer Immunotherapy Trials
Hoos, A., Eggermont, A. M. M., Janetzki, S., Hodi, F. S., Ibrahim, R., Anderson, A., Humphrey, R., Blumenstein, B., Old, L., & Wolchok, J. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq310 · Cited by 518
Measuring Response in Solid Tumors: Unidimensional Versus Bidimensional Measurement
James, K., Eisenhauer, E., Christian, M., Terenziani, M., Vena, D., Muldal, A., & Therasse, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.6.523 · Cited by 401
Nishino, M., Jagannathan, J. P., Ramaiya, N. H., & Van den Abbeele, A. D. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.09.4110 · Cited by 378
Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer
Buyse, M., Burzykowski, T., Carroll, K., Michiels, S., Sargent, D. J., Miller, L. L., Elfring, G. L., Pignon, J.-P., & Piedbois, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8836 · Cited by 354
Burzykowski, T., Buyse, M., Piccart-Gebhart, M. J., Sledge, G., Carmichael, J., Lück, H.-J., Mackey, J. R., Nabholtz, J.-M., Paridaens, R., Biganzoli, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8407 · Cited by 348
Rotte, A., Jin, J. Y., & Lemaire, V. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx686 · Cited by 344
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R. A., Mann, G. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx026 · Cited by 333
Necchi, A., Joseph, R. W., Loriot, Y., Hoffman-Censits, J., Perez-Gracia, J. L., Petrylak, D. P., Derleth, C. L., Tayama, D., Zhu, Q., Ding, B., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx518 · Cited by 299
Di Giacomo, A. M., Danielli, R., Guidoboni, M., Calabrò, L., Carlucci, D., Miracco, C., Volterrani, L., Mazzei, M. A., Biagioli, M., Altomonte, M., et al. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0642-y · Cited by 286
The RECIST criteria: implications for diagnostic radiologists
Padhani, A. R., & Ollivier, L. (2001) · The British Journal of Radiology · doi:10.1259/bjr.74.887.740983 · Cited by 263
Park, S. E., Lee, S. H., Ahn, J. S., Ahn, M.-J., Park, K., & Sun, J.-M. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.011 · Cited by 246
Escudier, B., Motzer, R. J., Sharma, P., Wagstaff, J., Plimack, E. R., Hammers, H. J., Donskov, F., Gurney, H., Sosman, J. A., Zalewski, P. G., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.037 · Cited by 240
Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations
Suzuki, C., Jacobsson, H., Hatschek, T., Torkzad, M. R., Bodén, K., Eriksson-Alm, Y., Berg, E., Fujii, H., Kubo, A., & Blomqvist, L. (2008) · RadioGraphics · doi:10.1148/rg.282075068 · Cited by 236
Schvartsman, G., Peng, S. A., Bis, G., Lee, J. J., Benveniste, M. F. K., Zhang, J., Roarty, E. B., Lacerda, L., Swisher, S., Heymach, J. V., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.034 · Cited by 215
RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
van Persijn van Meerten, E. L., Gelderblom, H., & Bloem, J. L. (2010) · European Radiology · doi:10.1007/s00330-009-1685-y · Cited by 191
George, S., Motzer, R. J., Hammers, H. J., Redman, B. G., Kuzel, T. M., Tykodi, S. S., Plimack, E. R., Jiang, J., Waxman, I. M., & Rini, B. I. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0775 · Cited by 181
Long, G. V., Weber, J. S., Larkin, J., Atkinson, V., Grob, J.-J., Schadendorf, D., Dummer, R., Robert, C., Márquez-Rodas, I., McNeil, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1588 · Cited by 176
Self-citationThiesse, P., Ollivier, L., Di Stefano-Louineau, D., Négrier, S., Savary, J., Pignard, K., Lasset, C., & Escudier, B. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.12.3507 · Cited by 168
Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy
Lee, L., Gupta, M., & Sahasranaman, S. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.591 · Cited by 156
Ronot, M., Bouattour, M., Wassermann, J., Bruno, O., Dreyer, C., Larroque, B., Castéra, L., Vilgrain, V., Belghiti, J., Raymond, É., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0114 · Cited by 156
Tumor Cell–Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy
Weiss, G. J., Beck, J., Braun, D. P., Bornemann-Kolatzki, K., Barilla, H., Cubello, R., Quan, W., Sangal, A., Khemka, V., Waypa, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0231 · Cited by 154
Fridlender, Z. G., Sun, J., Singhal, S. K., Kapoor, V., Cheng, G., Suzuki, E., & Albelda, S. Μ. (2010) · Molecular Therapy · doi:10.1038/mt.2010.159 · Cited by 130
Nishino, M., Ramaiya, N. H., Chambers, E. S., Adeni, A. E., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0193-2 · Cited by 119
Nishino, M., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-17 · Cited by 95
Zhao, B., Tan, Y., Bell, D. J., Marley, S. E., Guo, P., Mann, H., Scott, M. L. J., Schwartz, L. H., & Ghiorghiu, D. C. (2013) · European Journal of Radiology · doi:10.1016/j.ejrad.2013.02.018 · Cited by 92
Kazandjian, D. G., Keegan, P., Suzman, D. L., Pazdur, R., & Blumenthal, G. M. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.01.001 · Cited by 92
Girard, N., Jacoulet, P., Gainet-Brun, M., Elleuch, R., Pernet, D., Depierre, A., Dalphin, J., & Westeel, V. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181bbf223 · Cited by 72
Hoos, A., Wolchok, J. D., Humphrey, R. W., & Hodi, F. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3128 · Cited by 61
Nishino, M. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0134-0 · Cited by 57
Simon, A., Kourié, H. R., & Kerger, J. N. (2017) · 癌症:英文版 · doi:10.1186/s40880-017-0179-6 · Cited by 46
Remarkable response of nivolumab‐refractory lung cancer to salvage chemotherapy
Ogawara, D., Soda, H., Iwasaki, K., Suyama, T., Taniguchi, H., Fukuda, Y., & Mukae, H. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12543 · Cited by 39
Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma
Peggs, K. S., & Quezada, S. A. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.144 · Cited by 32
Abdel-Rahman, O. M. (2017) · Immunotherapy · doi:10.2217/imt-2017-0074 · Cited by 13
Cited by
Kato, K., Cho, B. C., Takahashi, M., Okada, M., Lin, C.-Y., Chin, K., Kadowaki, S., Ahn, M.-J., Hamamoto, Y., Doki, Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30626-6 · Cited by 1,213
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Zhang, Y., Chandra, V., Riquelme Sanchez, E., Dutta, P., Quesada, P. R., Rakoski, A., Zoltan, M., Arora, N., Baydogan, S., Horne, W., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190354 · Cited by 448
Metadata
- Authors
- Borcoman, E., Nandikolla, A., Long, G., Goel, S., & Le Tourneau, C.
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2018-05
- Volume
- 38
- Issue
- 38
- Pages
- 169-178
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W2806832126
- Cited by
- 262
- References
- 72
- FWCI
- 11.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.